Fig 5.

Commensal microbiota from ASB3^−/− mice enhances protection against DSS-induced experimental colitis in WT mice. (a) Schematic representation of the SiHo-CoHo strategy and DSS treatment. (b–d) Body weight (b and c) and survival (d) of SiHo-WT, SiHo-ASB3^−/−, Coho-WT, or Coho-ASB3^−/− mice during DSS-induced colitis. (SiHo-WT, n = 7; SiHo-ASB3^−/−, n = 5; Coho-WT, n = 6; and Coho-ASB3^−/−, n = 5). (e–g) Colon length (e), representative H&E staining (f), and DAI (g) of WT, ASB3^−/−, Coho-WT, or Coho-ASB3^−/− mice on day 8 after DSS induction. Scale bar, 50 µm. (h) The mRNA expression levels of IL-1β, IL-6, and TNF-α were determined by qPCR assay. (i) Schematic representation of the DSS challenge after ABX treatment. (j and k) Body weight changes (j) and survival (k) in WT and ASB3^−/− mice with or without combined ABX pretreatment for 5 days and 3% DSS for 6 days (WT, n = 7; ASB3^−/−, n = 7; ABX + WT, n = 8; and ABX + ASB3^−/−, n = 7). (l–n) DAI (l), colon length (m), and representative H&E staining (n) of WT, ASB3^−/−, ABX + WT, or ABX + ASB3^−/− mice on day 8 after DSS induction. Scale bar, 50 or 100 µm. (o) Colonic secretion of cytokines. Differences were determined in panels e, g, h, i, m, and o by unpaired Student’s t test and in panels d and k by log-rank test.